Agree, it also shows that the CD4/8 combination significantly improves efficacy. ( same thing over TCRX)
T cell-engaging bispecifics are designed to redirect T cells to cancer antigens. IMA401 is a next-gen T cell engaging receptor (TCER®) combining a high-affinity TCR domain against an HLA-A*02:01-presented MAGEA4/8 peptide, a low-affinity T cell-recruiting antibody and an Fc part for half-life extension. The target peptide exhibits a >5-fold higher density compared to the MAGEA4-derived peptide targeted by other bispecifics or cell therapies.
Again, I'm not 100% sure but i'm thinking there should be a press release over the next couple of days detailing the ESMO abstract in more layman's terms
I have assumed for a while that you live in Germany ( or Europe somewhere) and thanks for sharing the information on the production facility.
I'm in North America and just doing some Sunday afternoon research on a beautiful day here
Market Data 
Markets 
AI
